Validation of Interleukins and Other Cytokines Together With OCT Imaging for Rapid Infectious Keratitis Assessment
Launched by JOHANNES KEPLER UNIVERSITY OF LINZ · Nov 16, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to quickly diagnose and manage keratitis, which is an infection of the cornea in the eye that can be caused by bacteria or fungi. The researchers want to see how certain proteins in the body, known as cytokines, can help identify the types of germs causing the infection. They also aim to create a decision-making tool that will help doctors determine the best treatment based on the specific type of keratitis a patient has.
To participate in this study, you need to be at least 18 years old and have recently developed keratitis that hasn’t responded to treatment or has just appeared within the last 10 days. You will need to give your written permission to join the study. If you have had symptoms for more than 10 days, are pregnant, or have a serious health condition, you may not be eligible. Participants can expect to undergo non-invasive tests that will help with the rapid assessment of their condition, making it easier for doctors to provide the right care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women age of at least 18 years to 119 years
- • Written informed consent prior to study-related procedures
- • First presentation with keratitis (corneal epithelial ulceration, corneal edema and/or stromal infiltration with inflammatory cells) within 10 days.
- • Untreated keratitis or keratitis not responding to the given treatment
- Exclusion Criteria:
- Subjects will be excluded if one or more of the following criteria apply:
- • Symptoms for more than 10 days
- • Presence or history of a severe medical condition as judged by the clinical investigator
- • Pregnancy, planned pregnancy or lactating
About Johannes Kepler University Of Linz
Johannes Kepler University of Linz (JKU) is a leading research institution in Austria, renowned for its interdisciplinary approach and commitment to advancing knowledge across various fields, including health sciences. The university actively engages in clinical trials aimed at translating cutting-edge research into practical applications that enhance patient care and medical outcomes. JKU collaborates with healthcare professionals, academic institutions, and industry partners to foster innovation and ensure the ethical conduct of clinical research. Through its dedicated research centers and a robust framework for clinical studies, JKU plays a pivotal role in contributing to the advancement of medical science and improving public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Linz, Upper Austria, Austria
Patients applied
Trial Officials
Matthias Bolz, MD
Principal Investigator
JKU Linz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials